Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Non-Randomized Safety Study on Hypothermic Machine Perfusion With Omnisol Preservation Solution of Deceased Donor Kidneys Prior to Transplantation

NCT07920926 is registered in ClinicalTrials.gov with Vivalyx GmbH as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07920926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Non-Randomized Safety Study on Hypothermic Machine Perfusion With Omnisol Preservation Solution of Deceased Donor Kidneys Prior to Transplantation
Lead sponsor
Vivalyx GmbH
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
May 31, 2028
Enrollment
16 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease (esrd), kidney failure, kidney transplant, renal and urinary tract therapeutic procedures

Arms

As registered; 1 arm.

  • Hypothermic machine perfusion with Omnisol ExperimentalOmnisol organ preservation solution

    Recipients of a kidney from a donor after brain death (DBD) or a donor after cardiac death (DCD). After arrival at the transplant center according to standard of care, kidneys will be flushed with Omnisol and placed on the standard of care HMP machine for perfusion with Omnisol until transplantation.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Incidence of Delayed Graft Function 7 days post-transplantation.

    Incidence of delayed graft function, defined as the requirement for at least one dialysis session within the first 7 days after transplantation, excluding a single dialysis session performed solely for hyperkalemia or volume overload.

  • Graft Survival 30 days post-transplantation.

    30-day graft survival, censored and uncensored for recipient death.

Lead sponsor's other trials

Vivalyx GmbH, most recent start first.

Similar trials

Same condition (Kidney Failure, Chronic) and phase, most recent start first.